Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of zasocitinib in moderate to severe hidradenitis suppurativa
CTR20261070Phase 2Active
- Sponsor
- Takeda
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of zasocitinib in hidradenitis suppurativa (HS), sponsored by Takeda. Started Sep 2026; status: active.
02
Drugs
zasocitinib
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on CTR20261070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261070.